OPTIMA AF: Short-duration dual antithrombotic therapy after PCI in patients with atrial fibrillation
Med.IQ
2 min read
November 9, 2025
Highlights
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
Written by Med.IQ
About
The first healthtech knowledge company in Latin America. We connect, create, and disseminate content with the purpose of driving change and fostering new future possibilities for doctors and patients. We enable educational solutions.